DITROPAN XL

Ditropan Xl Adverse Events Reported to the FDA Over Time

How are Ditropan Xl adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Ditropan Xl, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Ditropan Xl is flagged as the suspect drug causing the adverse event.

Most Common Ditropan Xl Adverse Events Reported to the FDA

What are the most common Ditropan Xl adverse events reported to the FDA?

Drug Ineffective	21 (3.54%)
Dry Mouth	20 (3.37%)
Death	13 (2.19%)
Drug Interaction	13 (2.19%)
Hypertension	13 (2.19%)
Urinary Incontinence	11 (1.85%)
Fall	9 (1.52%)
Dry Throat	8 (1.35%)
Dyspnoea	8 (1.35%)
Lung Disorder	8 (1.35%)
Constipation	7 (1.18%)
	Show More
Loss Of Consciousness	7 (1.18%)
Macular Degeneration	7 (1.18%)
Confusional State	6 (1.01%)
Dehydration	6 (1.01%)
Intestinal Obstruction	6 (1.01%)
Medication Error	6 (1.01%)
Mental Status Changes	6 (1.01%)
Pollakiuria	6 (1.01%)
Tachycardia	6 (1.01%)
Urinary Tract Infection	6 (1.01%)
Amnesia	5 (.84%)
Asthenia	5 (.84%)
Chest Pain	5 (.84%)
Circulatory Collapse	5 (.84%)
Decreased Appetite	5 (.84%)
Product Quality Issue	5 (.84%)
Pyrexia	5 (.84%)
Transient Ischaemic Attack	5 (.84%)
Alanine Aminotransferase Increased	4 (.67%)
Aspartate Aminotransferase Increase...	4 (.67%)
Balance Disorder	4 (.67%)
Blood Pressure Decreased	4 (.67%)
Cholelithiasis	4 (.67%)
Dementia	4 (.67%)
Dysuria	4 (.67%)
Gait Disturbance	4 (.67%)
Nausea	4 (.67%)
Nocturia	4 (.67%)
Oedema Peripheral	4 (.67%)
Oesophageal Carcinoma	4 (.67%)
Pruritus	4 (.67%)
Vision Blurred	4 (.67%)
Weight Increased	4 (.67%)
Abdominal Mass	3 (.51%)
Abdominal Pain	3 (.51%)
Acne	3 (.51%)
Bacterial Infection	3 (.51%)
Blood Alkaline Phosphatase Increase...	3 (.51%)
Blood Cholesterol Increased	3 (.51%)
Cerebral Atrophy	3 (.51%)
Condition Aggravated	3 (.51%)
Dental Caries	3 (.51%)
Diarrhoea	3 (.51%)
Disease Progression	3 (.51%)
Dry Skin	3 (.51%)
Fatigue	3 (.51%)
Fluid Retention	3 (.51%)
Glaucoma	3 (.51%)
Headache	3 (.51%)
Intervertebral Disc Protrusion	3 (.51%)
Large Intestine Perforation	3 (.51%)
Liver Disorder	3 (.51%)
Myocardial Infarction	3 (.51%)
Obstructive Uropathy	3 (.51%)
Pain	3 (.51%)
Rectal Haemorrhage	3 (.51%)
Renal Haemorrhage	3 (.51%)
Therapeutic Response Decreased	3 (.51%)
Vomiting	3 (.51%)
Weight Decreased	3 (.51%)
Wheezing	3 (.51%)
Abnormal Faeces	2 (.34%)
Abortion Spontaneous	2 (.34%)
Ammonia Increased	2 (.34%)
Anorexia	2 (.34%)
Aphasia	2 (.34%)
Appendicitis Perforated	2 (.34%)
Arthropathy	2 (.34%)
Atrial Fibrillation	2 (.34%)
Bile Duct Stone	2 (.34%)
Biliary Tract Disorder	2 (.34%)
Bladder Pain	2 (.34%)
Bladder Prolapse	2 (.34%)
Bladder Spasm	2 (.34%)
Blood Glucose Decreased	2 (.34%)
Blood Glucose Increased	2 (.34%)
Blood Potassium Decreased	2 (.34%)
Blood Urine Present	2 (.34%)
Breast Cancer Metastatic	2 (.34%)
Cardiac Failure	2 (.34%)
Cerebrovascular Accident	2 (.34%)
Chromaturia	2 (.34%)
Cognitive Disorder	2 (.34%)
Cystitis	2 (.34%)
Disorientation	2 (.34%)
Drug Administered At Inappropriate ...	2 (.34%)
Drug Exposure During Pregnancy	2 (.34%)
Dyskinesia	2 (.34%)
Encephalopathy	2 (.34%)
Eye Pain	2 (.34%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Ditropan Xl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ditropan Xl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Ditropan Xl

What are the most common Ditropan Xl adverse events reported to the FDA?

Therapeutic And Nontherapeutic Effe...	38 (6.4%)
Urinary Tract Signs	36 (6.06%)
Respiratory	28 (4.71%)
Neurological	21 (3.54%)
Salivary Gland Conditions	21 (3.54%)
Gastrointestinal Signs	19 (3.2%)
Infections - Pathogen Unspecified	19 (3.2%)
Fatal Outcomes	13 (2.19%)
Injuries	13 (2.19%)
Vascular Hypertensive	13 (2.19%)
Gastrointestinal Motility And Defec...	12 (2.02%)
	Show More
Medication Errors	11 (1.85%)
Mental Impairment	11 (1.85%)
Hepatobiliary	10 (1.68%)
Cardiac Arrhythmias	9 (1.52%)
Electrolyte And Fluid Balance Condi...	9 (1.52%)
Epidermal And Dermal Conditions	9 (1.52%)
Cardiac And Vascular Investigations	8 (1.35%)
Deliria	8 (1.35%)
Dental And Gingival Conditions	8 (1.35%)
Renal Disorders	8 (1.35%)
Appetite And General Nutritional	7 (1.18%)
Central Nervous System Vascular	7 (1.18%)
Gastrointestinal Neoplasms Malignan...	7 (1.18%)
Joint	7 (1.18%)
Ocular Structural Change, Deposit A...	7 (1.18%)
Physical Examination Topics	7 (1.18%)
Gastrointestinal Stenosis And Obstr...	6 (1.01%)
Product Quality Issues	6 (1.01%)
Psychiatric	6 (1.01%)
Vision	6 (1.01%)
Bacterial Infectious	5 (.84%)
Body Temperature Conditions	5 (.84%)
Bone And Joint Injuries	5 (.84%)
Coronary Artery	5 (.84%)
Decreased And Nonspecific Blood Pre...	5 (.84%)
Disturbances In Thinking	5 (.84%)
Gallbladder	5 (.84%)
Movement Disorders	5 (.84%)
Musculoskeletal And Connective Tiss...	5 (.84%)
Skin Appendage Conditions	5 (.84%)
Anxiety Disorders	4 (.67%)
Bile Duct	4 (.67%)
Bronchial Disorders	4 (.67%)
Glaucoma And Ocular Hypertension	4 (.67%)
Lipid Analyses	4 (.67%)
Metabolic, Nutritional And Blood Ga...	4 (.67%)
Procedural And Device Related Injur...	4 (.67%)
Bladder And Bladder Neck Disorders	3 (.51%)
Chemical Injury And Poisoning	3 (.51%)
Enzyme	3 (.51%)
Eye	3 (.51%)
Gastrointestinal Conditions	3 (.51%)
Gastrointestinal Hemorrhages	3 (.51%)
Gastrointestinal Ulceration And Per...	3 (.51%)
Headaches	3 (.51%)
Heart Failures	3 (.51%)
Hematology Investigations	3 (.51%)
Hepatic And Hepatobiliary	3 (.51%)
Inner Ear And Viiith Cranial Nerve	3 (.51%)
Musculoskeletal And Connective Tiss...	3 (.51%)
Renal And Urinary Tract Investigati...	3 (.51%)
Seizures	3 (.51%)
Structural Brain	3 (.51%)
Therapeutic Procedures And Supporti...	3 (.51%)
Abortions And Stillbirth	2 (.34%)
Bone And Joint Therapeutic Procedur...	2 (.34%)
Breast Neoplasms Malignant And Unsp...	2 (.34%)
Cardiac Disorder Signs	2 (.34%)
Encephalopathies	2 (.34%)
Investigations, Imaging And Histopa...	2 (.34%)
Peripheral Neuropathies	2 (.34%)
Pleural	2 (.34%)
Prostatic Disorders	2 (.34%)
Protein And Amino Acid Metabolism	2 (.34%)
Reproductive Neoplasms Male Maligna...	2 (.34%)
Upper Respiratory Tract Disorders	2 (.34%)
Vascular Hemorrhagic	2 (.34%)
Water, Electrolyte And Mineral	2 (.34%)
Anal And Rectal Conditions	1 (.17%)
Angiedema And Urticaria	1 (.17%)
Cranial Nerve Disorders	1 (.17%)
Demyelinating	1 (.17%)
Glucose Metabolism Disorders	1 (.17%)
Miscellaneous And Site Unspecified ...	1 (.17%)
Mood Disorders	1 (.17%)
Neuromuscular	1 (.17%)
Ocular Hemorrhages And Vascular	1 (.17%)
Pulmonary Vascular	1 (.17%)
Renal And Urinary Tract Neoplasms M...	1 (.17%)
Respiratory And Mediastinal Neoplas...	1 (.17%)
Skin And Subcutaneous Tissue Therap...	1 (.17%)
Viral Infectious	1 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Ditropan Xl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ditropan Xl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.